Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study

NCT02241629 Phase 2 COMPLETED

A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.

Details

Lead sponsor	Sihuan Pharmaceutical Holdings Group Ltd.
Phase	Phase 2
Status	COMPLETED
Enrolment	180
Start date	2014-08
Completion	2015-02

Conditions

• Motion Sickness

Interventions

• placebo
• levo phencynonate hydrochloride

Primary outcomes

• the symptoms of seasickness — Two hours of voyage
  Investigators should assess the symptoms of seasickness for subjects according to sea sickness severity scale.

Countries

China